Market Cap | 4.83M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -66.09M | Forward P/E | -0.16 | EPS next Y | - | 50D Avg Chg | -2.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -68.00% |
Dividend | N/A | Price/Book | 0.26 | EPS next 5Y | - | 52W High Chg | -90.00% |
Recommedations | 3.00 | Quick Ratio | 4.78 | Shares Outstanding | 67.72M | 52W Low Chg | 43.00% |
Insider Own | 13.13% | ROA | -43.58% | Shares Float | 58.78M | Beta | 1.22 |
Inst Own | 0.17% | ROE | -138.06% | Shares Shorted/Prior | 2.23M/3.27M | Price | 0.07 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,413,021 | Target Price | - |
Oper. Margin | - | Earnings Date | Mar 28 | Volume | 219,819 | Change | -1.11% |
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
HC Wainwright & Co. | Neutral | Mar 7, 23 |
SVB Leerink | Market Perform | Mar 1, 23 |
HC Wainwright & Co. | Buy | Aug 26, 22 |
Cowen & Co. | Market Perform | Aug 16, 22 |
Truist Securities | Hold | Aug 16, 22 |
BMO Capital | Outperform | Aug 15, 22 |
Piper Sandler | Neutral | Aug 12, 22 |
SVB Leerink | Outperform | Aug 5, 22 |
Piper Sandler | Overweight | May 19, 22 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
HOMBACH ROBERT J. | Director Director | Nov 11 | Buy | 2.4 | 80,000 | 192,000 | 229,100 | 11/16/21 |